Key Points
Indian pharmaceutical giants, including Dr. Reddys Laboratories and Emcure Pharmaceuticals, are going to produce generic versions of lenacapavir, an HIV prevention drug, following non-exclusive licensing agreements signed with Gilead Sciences, Inc...
These agreements will allow the companies to manufacture and distribute lenacapavir to 120 resource-limited countries, pending regulatory approvals, according to Gilead's official statement...
Gilead's collaboration with pharmaceutical firms across the globe, also including Eva Pharma, Ferozsons Laboratories Limited, Hetero and Mylan, a subsidiary of Viatris, ensures that, once approved, generic versions of the drug will be made available quickly and at low cost in high-need regions in 120 countries, including India.. . ) ..
You might be interested in
Hope like never before — a drug that promises 100% protection from HIV
27, Jun, 24Lenacapavir, developed by Gilead Sciences, was tested as a pre-exposure prophylaxis in African women & is now being tested in other groups who are among the most vulnerable to HIV.
Twice-yearly shot proves 100% effective in preventing HIV infection: Study
28, Jul, 24The findings of a new study highlight the potential of a drug called lenacapavir as a revolutionary HIV prevention method.